Department of General, Visceral and Tumor Surgery, University of Cologne, 50931 Cologne, Germany.
J Oncol. 2009;2009:139590. doi: 10.1155/2009/139590. Epub 2009 Nov 22.
Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell lung cancer (NSCLC) additional diagnostic tools are urgently needed. Gene expression of Cyclooxygenase-2 (COX-2) has been linked to prognosis in patients with NSCLC. The role of the COX-2 926G>C Single Nucleotide Polymorphism (SNP) in patients with NSCLC remains unclear. The aim of this study was to investigate the potential of the COX-2 926G>C SNP as a molecular marker in this disease. Methods. COX-2 926G>C SNP was analyzed in surgically resected tumor tissue of 85 patients with NSCLC using a PCR-based RFLP technique. Results. The COX-2 926G>C SNP genotypes were detected with the following frequencies: GG n = 62 (73%), GC n = 20 (23%), CC n = 3 (4%). There were no associations between COX-2 SNP genotype and histology, grading or gender detectable. COX-2 SNP was significantly associated with tumor stage (P = .032) and lymph node status (P = .016, Chi-square test). With a median followup of 85.9 months, the median survival was 59.7 months. There were no associations seen between the COX-2 SNP genotype and patients prognosis. Conclusions. The COX-2 926G>C SNP is detectable at a high frequency in patients with NSCLC. The COX-2 926G>C SNP genotype is not a prognostic molecular marker in this disease. However, patients with the GC or CC genotype seem more susceptible to lymph node metastases and higher tumor stage than patients with the GG genotype. The results suggest COX-2 926G>C SNP as a molecular marker for lymph node involvement in this disease.
背景。为了进一步提高非小细胞肺癌（NSCLC）患者的筛查、诊断和治疗水平，迫切需要额外的诊断工具。环氧化酶-2（COX-2）的基因表达与 NSCLC 患者的预后相关。COX-2 926G>C 单核苷酸多态性（SNP）在 NSCLC 患者中的作用尚不清楚。本研究旨在探讨 COX-2 926G>C SNP 作为该疾病分子标志物的潜力。方法。采用基于 PCR 的 RFLP 技术分析 85 例 NSCLC 手术切除肿瘤组织中的 COX-2 926G>C SNP。结果。检测到 COX-2 926G>C SNP 基因型的频率如下：GG 型 n = 62（73%），GC 型 n = 20（23%），CC 型 n = 3（4%）。COX-2 SNP 基因型与组织学、分级或性别之间没有关联。COX-2 SNP 与肿瘤分期（P =.032）和淋巴结状态（P =.016，卡方检验）显著相关。中位随访 85.9 个月，中位生存期为 59.7 个月。COX-2 SNP 基因型与患者预后之间未见关联。结论。COX-2 926G>C SNP 在 NSCLC 患者中可检测到较高的频率。COX-2 926G>C SNP 基因型不是该疾病的预后分子标志物。然而，GC 或 CC 基因型的患者似乎比 GG 基因型的患者更容易发生淋巴结转移和更高的肿瘤分期。结果表明 COX-2 926G>C SNP 可作为该疾病淋巴结受累的分子标志物。
